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ABSTRACT 
Toxicity risk assessment for chemical-induced human health hazards relies mainly on data 
obtained from animal experimentation, human studies and epidemiology. In vitro testing for acute 
toxicity based on cytotoxicity assays predicts 70 – 80 % of rodent and human toxicity. The 
nervous system is particularly vulnerable to chemical exposure which may result in different 
toxicity features. Acute human toxicity related to adverse neuronal function is usually a result of 
over-excitation or depression of the nervous system. The major molecular and cellular 
mechanisms involved in such reactions include GABAergic, glutamatergic and cholinergic 
neurotransmission, regulation of cell and mitochondrial membrane potential, and those critical for 
maintaining central nervous system functionality, such as controlling cell energy. In this work, a 
set of chemicals that are used in pharmacy, industry, biocide treatments or are often abused by 
drug users are tested for their effects on GABAA receptor activity, GABA and glutamate transport, 
cell membrane potential and cell viability in primary neuronal cultures. GABAA receptor function 
was inhibited by compounds for which seizures have been observed after severe human 
poisoning. Commonly abused drugs inhibit GABA uptake but not glutamate uptake. Most 
neurotoxins altered membrane potential. The GABAA receptor, GABA uptake and cell membrane 
potential assays were those that identified the highest number of chemicals as toxic at low 
concentrations. These results show that in vitro cell assays may identify compounds that produce 
acute neurotoxicity in humans, provided that in vitro models expressing neuronal targets relevant 
for acute neural dysfunctions are used.  
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1. Introduction 
Toxicity risk assessment for chemical-induced human health hazards relies mainly on 
data obtained from animal experimentation, human studies and epidemiology. The nervous 
system is particularly vulnerable to chemical exposure; its complexity results in multiple potential 
target sites with different toxicity features. Acute human toxicity related to adverse neuronal 
function is mainly a result of over-excitation or depression of the peripheral or central nervous 
system (CNS). The major molecular and cellular mechanisms involved in such effects include 
GABAergic, glutamatergic and cholinergic neurotransmission, regulation of cell and mitochondrial 
membrane potential, and those critical for maintaining CNS functionality, such as controlling cell 
energy. Severe disturbance of these mechanisms may result in convulsions, fatal central 
depression and cell death. Compared to other tissues, nerve cells have little ability to replace 
themselves or regenerate, which limits full recovery when cell damage occurs. Therefore, it is 
crucial to develop models that predict and can detect neurotoxic chemicals. Recently 
implemented regulations such as the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) in the EU (EC 1907/2006 directive) 
(http://ec.europa.eu/environment/chemicals/reach/reach_intro.htm), and the High Production 
Volume (HPV) Program in the USA (http://www.epa.gov/HPV), are designed to manage the risks 
from chemicals and provide safety information on them. In this context, non-animal testing 
allowing high-throughput analysis of a huge number of chemicals is foreseen and promoted in the 
REACH program. 
In vitro testing for acute toxicity based on general cytotoxicity assays, such as the 
Registry of Cytotoxicity (RC) and the Multicentre Evaluation of In Vitro Cytotoxicity (MEIC), can 
predict 70 – 80 % of rodent and human toxicity [10,19,22]. There are many reasons for the 20 – 
30 % failure: i) chemical metabolism, ii) barrier passage, iii) biokinetics, and iv) organ-specific 
toxicity (neurotoxicity, hepatotoxicity, nephrotoxicity, etc.). Alternative testing strategies, including 
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biokinetic models and endpoints for organ specific toxicity, aim to define alerts and correctors to 
improve this failure rate in prediction when using exclusively cytotoxicity-based assays. Such 
strategies would either reveal factors that improve the correlation between in vitro cytotoxic data 
and acute human toxicity, or define alerts that identify outliers (compounds for which the 
cytotoxicity in vitro data give a false evaluation of their acute human toxicity).  
Neurotoxic events are the consequence of the failure of one or several molecular 
mechanisms (see [30,39]) such as the functioning of ion channels (voltage- or ligand-operated 
ionotropic receptors, such as GABAA, NMDA, AMPA/kainate, and nicotinic acetylcholine), the 
transport of amino acidergic and aminergic neurotransmitters, neurotransmitter synthesis and 
degradation involving enzymes, cell energy control, the regulation of cell and mitochondrial 
membrane potential, intracellular calcium homeostasis and control of the production and 
inactivation of reactive oxygen species. The amino acids γ-aminobutyric acid (GABA) and 
glutamate are, respectively, the most common inhibitory and excitatory neurotransmitters in the 
CNS. Once released into the synapse they act on ionotropic receptors of GABA (GABAA) and 
glutamate (NMDA and AMPA/kainate). Whereas excessive potentiation of the GABAA receptor 
activity results in central depression, inhibition of GABAA receptor activity results in overall 
excitatory symptoms and convulsions in mammals [27,28]. Conversely, excessive activation of 
ionotropic glutamate receptors results in excitatory symptoms and in degeneration of neurons 
through a process known as excitotoxicity [23,31]. 
In vitro evaluation of these neuronal specific and general endpoints requires well-
characterized cell culture systems. Primary neuronal cultures of cortical and cerebellar granule 
cells are enriched in GABAergic and cholinergic neurons [41,42,48], and in glutamatergic neurons 
[14,38], respectively. Transport of the neurotransmitters GABA and glutamate can be evaluated 
by determining the uptake of [3H]GABA in cortical neurons and of [3H]aspartate or [3H]glutamate 
in cerebellar granule neurons, respectively (aspartate being an analogue of glutamate that is 
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taken up by the cells through the glutamate transport system). Furthermore, both cultured cortical 
neurons and cerebellar granule cells express functional ionotropic GABAA and glutamate 
receptors, which are neural targets for depressant, convulsant and excitotoxic compounds. For a 
review of the functional characteristics of these in vitro systems see [41].  
In the present work we select a set of compounds (Table 1 in Supplementary Material) 
based on the European project ACUTETOX (www.acutetox.org). We then test the effect of these 
compounds on several neuronal functional endpoints and on cell viability in primary cultured 
neurons. Most of the reference compounds were chosen from the MEIC project [9] and the 
NICEATM/ECVAM In Vitro Cytotoxicity Validation Study [1] and are pharmaceuticals, pesticides, 
and industrial chemicals, for which data on their acute human toxicity exist. Both compounds 
whose acute systemic toxicity was well predicted by general cytotoxicity tests and compounds 
identified as outliers (i.e., their toxicity was poorly predicted) were included in the list. In addition, 
some of the reference compounds were selected as positive control compounds for specific 
target endpoints in the nervous system, kidney and liver. The ACuteTox project aims to improve 
predictability by combining a handful of simple and robust tests that measure complementary 
parameters such as absorption, distribution and metabolism, as well as organ specificity. The 
objective of these research activities is to increase knowledge of the mechanisms by which these 
compounds cause toxicity and to identify corrector/alert assays in order to improve the in vivo / in 
vitro correlation. The compounds selected have been tested by different research groups using 
relevant in vitro assays and in silico approaches including basal cytotoxicity, barrier passage, 
metabolism, hepatotoxicity, renal toxicity and neurotoxicity. Here we present results concerning 
GABAergic and glutamatergic neurotransmission (as the main depressant and excitatory neural 
systems) and cell membrane potential (which determines neural electrical excitability) in primary 
cultures of cortical neurons and of cerebellar granule cells.  
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2. Methods 
 
2.1. Materials  
Pregnant NMRI mice (16th day of gestation) and 7-day-old NMRI mice were obtained 
from Charles River, Iffa Credo (St. Germain-sur-l’Arbreste, France). Plastic multi-well culture 
plates were purchased from NunclonTM NuncTM (Roskilde, Germany). Foetal calf serum was 
obtained from Gibco (Invitrogen, Barcelona, Spain) and Dulbecco’s modified minimum essential 
medium (DMEM) from Biochrom (Berlin, Germany). 36Cl- (111– 532 Mbq/g), [3H]-flunitrazepam (≈ 
3 TBq/mmol), [3H]-GABA (≈ 3 TBq/mmol) and [3H]-D-aspartate (1 TBq/mmol) were obtained from 
Amersham Life Science (Buckinghamshire, UK). Optiphase Hisafe 2 liquid scintillation cocktail 
was obtained from Wallace Oy (Turku, Finland). The FMP membrane potential assay kit (blue) 
was from Molecular Devices (Sunnyvale, CA, USA). 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenyl-
formazan (MTT) was from Sigma Chemical Co. (St. Louis, MO, USA) and the lactate 
dehydrogenase (LDH) cytotoxicity kit was from Roche (Manheim, Germany). Fluo-3/AM was 
obtained from Molecular Devices. 
 
2.2. Chemicals  
Of the first set of reference compounds: acetaminophen, acetylsalicylic acid, 
carbamazepine, cycloheximide, diazepam, digoxin, mercury (II) chloride, phenobarbital, sodium 
lauryl sulphate (SDS), verapamil hydrochloride, nicotine, (±)methadone hydrochloride, d-
amphetamine sulphate, sodium valproate, pentachlorophenol and isopropyl alcohol were 
obtained from Sigma Chemical Co; atropine sulphate monohydrate, caffeine, colchicine and 
ethanol were obtained from Fluka (St. Louis, MO, USA); and malathion, lindane and glufosinate 
ammonium were obtained from Riedel de Haen (St. Louis, MO, USA). 
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Of the second set of reference compounds: 5-fluorouracil, tert-butylhydroperoxide, 
rifampicine, tetracycline hydrochloride, cadmium(II) chloride, cyclosporin A, 17α-ethynylestradiol, 
lithium sulphate, warfarin, 2,4-dichlorophenoxyacetic acid, strychnine, pyrene, 
hexachlorobenzene, amiodarone hydrochloride, parathion, dichlorvos, physostigmine, cis-
diamminiumplatinum (II) dichloride, (-)-epinephrine bitartrate, ochratoxin A, sodium chloride, 
thallium sulphate, sodium selenate, dimethylformamide, amitriptyline hydrochloride, ethylene 
glycol, methanol, lithium sulphate, arsenic trioxide, chloral hydrate, acetonitrile and propanolol 
hydrochloride were obtained from Sigma Chemical Co; acryaldehyde, orphenadrine hydrochloride 
and diethylene glycol were obtained from Fluka ; and diequat dibromide was obtained from Riedel 
de Haen. 
The chemicals were dissolved and diluted in HEPES-buffered saline solution or in 
DMSO. When dissolved in DMSO, a 200 x concentration was prepared, thus the concentration of 
DMSO in the testing solution was 0.5%. Controls contained the same amount of DMSO, when so 
required. 
             
2.3. Neuronal Cultures  
Primary cultures of cortical neurons were obtained from neocortices from 16-day-old mice 
foetuses, using 10 – 12 foetuses from one pregnant mouse for each culture preparation. 
Pregnant animals were anesthetized with isofluorane (FORANE®, Abbott Laboratories SA, 
Madrid, Spain) and killed by cervical dislocation. Primary cultures of cerebellar granule cells were 
obtained from 7-day-old pups, using a litter of 10 pups per culture. Pups were killed by 
decapitation.  
Primary cultures were prepared as previously described [3,15]. In brief, the neocortices 
from foetuses or cerebella from pups were minced, with cells then dissociated by mild 
trypsinization (0.02 – 0.025 % w/v) at 37ºC for 10 min followed by trituration in a DNAse solution 
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(0.004% w/v) containing a soybean trypsin inhibitor (0.05% w/v). The cells were re-suspended in 
modified DMEM solution (31 mM glucose and 0.2 mM glutamine), supplemented with insulin, 
penicillin and 10% foetal calf serum, containing 5 mM KCl for cortical neurons and 25 mM KCl for 
cerebellar granule cells. The cell suspension (1.6 x 106 cells/ml) was seeded in 24-well plates (0.5 
ml/well) and 96-multi-well plates (0.1 ml/well), pre-coated with poly-D-lysine, and incubated for 6-
9 days in a humidified 5% CO2 / 95% air atmosphere at 36.8ºC without changing the culture 
medium. After 24 – 48 h in culture, the  primary cultures were treated with the mitotic inhibitor (5 
µM 5-fluoro-2’-deoxyuridine and 20 µM uridine) to prevent glial proliferation. Cells were fully 
differentiated after 6 - 8 days in vitro and ready to use for the testing assays. Usually, 6 plates of 
24 wells or 12 plates of 96 wells (filling the external wells with water) were obtained from each 
culture preparation. 
Animals were handled in compliance with the protocols of the University of Barcelona, as 
approved by the Generalitat de Catalunya, Spain, in accordance with EU guidelines, and in 
compliance with the Office of Laboratory Animal Welfare (OLAW) / National Institutes of Health 
(NIH). 
 
2.4. Chloride influx 
Chloride influx was determined as 36Cl- uptake in intact cell cultures of cortical neurons 
grown in 24-well plates [15,45]. Briefly, the culture medium was replaced by a pre-warmed Earle’s 
balanced salt solution (EBSS: 116 mM NaCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 1 mM NaH2PO4, 
15.2 mM NaHCO3 and 5.5 mM glucose, adjusted to pH 7.4) and cell cultures were incubated in a 
humidified 5% CO2/ 95% air atmosphere at 36.8ºC. After 30 min incubation, the buffer was 
replaced by new EBSS solution and incubation continued for an additional 15 min. Cells were 
pre-incubated with test agent solutions prepared in EBSS for 10 min at room temperature. After 
this, the cells were incubated for 10 sec with 225 μl HEPES-buffer (HBSS: 136 mM NaCl, 5.4 mM 
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KCl, 1.2 mM CaCl2, 1.4 mM MgCl2, 1.0 mM NaH2P04, 10 mM HEPES and 9 mM glucose, 
adjusted to pH 7.3) containing 36Cl- (0.4 µCi/ml), 5 µM or 100 µM GABA and different 
concentrations of the test agents. 100 µM picrotoxinin was used as a positive control of the 
assay. Plates where picrotoxinin did not inhibit GABA-induced 36Cl- uptake were discarded. After 
removing the 36Cl- solution, each well was immediately rinsed four times with 1.5 ml cold HBSS 
solution. Cells were lysed by water-induced hyposmotic shock, and radioactivity was determined 
by liquid scintillation counting in a Wallac 1414 WinspectralTM.  
 
2.5. Flunitrazepam binding assay 
[3H]-Flunitrazepam binding to intact cultured cells of cortical neurons was performed in 
24-well plates [15]. In brief, attached cells were rinsed with pre-warmed (37ºC) HBSS solution 
and pre-incubated together with this solution containing different concentrations of the test agents 
for 10 min at 25ºC. The HBSS solutions were then replaced with fresh solutions containing 
different concentrations of the compounds in the presence of 100 µM GABA and 2-4 nM [3H]- 
flunitrazepam. Basal flunitrazepam binding performed in the absence of GABA was subtracted to 
obtain GABA-enhanced flunitrazepam binding. Following 30 min incubation at 25ºC, the medium 
was aspirated and the cells were quickly rinsed four times with cold HBSS solution. Cells were 
digested in 0.2 M NaOH overnight and bound radioactivity was determined by liquid scintillation 
counting.  
 
2.6. GABA uptake 
GABA transport was determined as [3H]-GABA uptake in primary cultures of cortical 
neurons. Intact cortical cultured cells were rinsed with pre-warmed HBSS solution and incubated 
for 10 min at 35ºC in the same buffer containing 4 nM [3H]-GABA, 10 µM GABA (approximate Km 
for GABA in cortical neurons [44]) and different concentrations of the test agents. The assay was 
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terminated by rapid washing with ice-cold buffer. The cells were digested with 0.2 M NaOH 
overnight and incorporated radioactivity was determined by liquid scintillation counting. Specific 
uptake was determined by subtracting radioactivity measurements carried out in the presence of 
5 mM GABA.  
 
2.7. Glutamate Uptake 
Glutamate transport was determined as [3H]-D-aspartate uptake, since D-aspartate is a 
non-metabolized substrate for glutamate transporters, as previously reported [12]. Primary 
cultures of cerebellar granule cells were washed three times with HBSS solution and incubated 
with HBSS buffer containing [3H]-D-aspartate (3 nM), 60 µM glutamate (Km for glutamate 
transport in cerebellar granule cells [47]) and different concentrations of the test agent for 10 min 
at 36ºC. Cells were digested in 0.2 M NaOH overnight and incorporated radioactivity was 
determined by liquid scintillation counting. Specific uptake was determined by subtracting 
radioactivity measurements carried out in the presence of 1 mM glutamate.   
 
2.8. Intracellular calcium in Mg2+-free buffer 
The increase of intracellular calcium in cultured cortical neurons in Mg2+-free buffer was 
used to determine the activity of chemicals on N-methyl-D-aspartic acid (NMDA) receptors, as 
previously described [2,3]. In brief, NMDA receptor function was determined by measuring the 
increase in Fluo-3 fluorescence in Mg2+-free buffer to relieve the physiological blocking of the 
NMDA receptor by Mg2+. Cultured cells were incubated with 9 µM Fluo-3 AM for 1 h at 36.8ºC in 
HBSS solution. Excess Fluo-3 AM was rinsed away and the cells were treated with test agents in 
the absence and in the presence of 5 or 100 µM NMDA. Fluorescence (Ex 485 ⁄ Em 530) was 
immediately determined in a fluorimeter plate reader (SpectraMax GeminisXS; Molecular Devices 
Corporation, Sunnyvale, CA, USA).  
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2.9. Fluorescent Membrane Potential 
The FMP Membrane Potential Assay kit-BLUE (Explorer kit) (FMP) (Molecular Devices 
Corporation) was used to detect changes in the voltage across cell membranes. Cultured cortical 
neurons grown for 6-9 days in 96-well plates were rinsed with pre-warmed Hanks solution (136.9 
mM NaCl, 1.3 mM CaCl2, 5.4 mM KCl, 0.4 mM KH2PO4, 0.5 mM MgCl2, 0.4 mM MgSO4, 4.2 mM 
NaHCO3, 0.3 mM Na2HPO4, 8 mM HEPES, 5.5 mM glucose) and incubated with Hanks solution 
for 20 min at 37ºC in darkness. After this, the cells were loaded with FMP and incubated for 30 
min at 37ºC. After measuring basal fluorescence, Hanks solution containing different 
concentrations of the test agent (5x) was added and fluorescence read after 5 min. Fluorescence 
was determined in a bottom-reader fluorimeter plate reader (Cytofluor 2350, Millipore) at an 
Ex/Em of 530/590 nm. 30 mM KCl was used as a positive control of cell membrane depolarization 
and to normalize fluorescence values.  
 
2.10. Cell viability 
The LDH assay was used to determine cell membrane leakage. Cultured cortical neurons 
grown in 96-well plates were rinsed and incubated for 30 min at 36ºC with HEPES buffered saline 
solution containing different concentrations of the test agents. Control wells contained the vehicle, 
and Triton X-100 was added to three wells to obtain maximum cytotoxicity. The activity of the 
released LDH was determined in an enzymatic test by using the Cytotoxicity Detection Kit from 
Roche, according to the manufacturer’s instructions. In brief, after removing the incubation 
solution, 100 μl of the LDH Reagent Solution was added to each well. The cells were incubated in 
the dark at room temperature for 30 min, in an orbital shaker. Thereafter, the enzymatic reaction 
was stopped by adding 50 µl 1M HCl to each well. After removing the bubbles, the absorbance 
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was measured at 492 nm in a spectrophotometer plate reader, using a reference wavelength of 
620 nm (iEMS Reader MF; Labsystems, Helsinki, Finland ). 
The reduction of MTT to a coloured formazan salt by mitochondrial reducing activity, was 
measured as previously described [15]. Briefly, cells grown in 96-well plates were rinsed and 
incubated for 30 min at 36ºC with HEPES buffered saline solution containing different 
concentrations of the test agents or vehicle. Following the incubation period, the cells were rinsed 
with HBSS solution and then incubated for 20 min at 37ºC with 100 µL MTT reagent solution 
(0.25 mg/ml). After removal of the MTT solution, 100 µl of solubilization solution (SDS 5% w/v) 
was added to each well and the cells were kept overnight at 37ºC in darkness. Absorbance was 
measured at a wavelength of 560 nm using a spectrophotometer plate reader (iEMS Reader MF; 
Labsystems). 
 
2.11. Data analysis 
Results are expressed as mean ± S.E.M of at least 3 independent experiments. 
Concentration-response curves were fitted to sigmoid curves using the GraphPad Prism 
(GraphPad Software Inc, San Diego, CA, USA). 5 – 7 concentration points, each in duplicate or 
triplicate, were used in each experiment. Concentration values are given in mol/L (M). The two-
tailed Student’s t-test was used to compare mean values. 
 
2.12. Human data.  
Human blood 50% lethal concentrations (LC50), expressed in moles per litre (M), were 
adapted from recently published data [37]. The data for the chemicals used in this study were 
taken from Acutoxbase which is a part of the integrated ACuteTox project (2005-2009) under the 
EU 6th Framework Programme [7]. At present, Acutoxbase includes 97 reference chemicals of 
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different origin (drugs, industrial chemicals, biocides, etc.). Acutoxbase will be made accessible 
for the scientific community after the completion of the ACuteTox project.   
Human blood concentration data, at acute poisoning, was collected from clinical and 
forensic sub-lethal and lethal case reports. The information was obtained from the MEIC project 
[8], MEIC monographs (www.cctoxconsulting.a.se), papers in international journals, poison 
information centres in several countries, and several on-line databases [7].  
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3. Results 
The first set of reference compounds were evaluated against the different neuronal assays used 
in this work. After completion of the study, the GABAA receptor assay was selected (see below) 
for the testing of the additional compounds included in the second set of reference compounds.  
 
3.1. In vitro assays of GABA neurotransmission 
We determined the effects on the GABAA receptor of the whole set of reference 
compounds. 23 out of the 58 compounds tested inhibited GABAA receptor activity, as determined 
by measuring the 36Cl- uptake induced by 100 µM GABA. Table 1 shows the IC20, IC50, IC80 and 
Imax values. Diazepam, phenobarbital, mercuric chloride, chloral hydrate and isopropyl alcohol 
increased GABA-induced Cl- influx (Table 1). All together, twenty-eight out of the fifty-eight 
compounds tested positive against the GABAA receptor. The assay was developed as a non-
robotic, medium-throughput, screening assay using 24-well plates, performing a whole test agent 
concentration-response curve in each plate. Throughout this work, the intra-assay variability 
(repeatability) of 36Cl- influx for the control wells in each individual plate accounted for 12 ± 0.6 % 
(3 replicates in each plate; n = 105 plates). The intra-assay variability of 36Cl- influx for the control 
wells corresponding to different plates from 25 culture preparations (3 – 6 plates for each 
preparation) accounted for 17 ± 3 %.  
We have previously shown that [3H]-flunitrazepam binding in primary cultured neurons is 
increased by GABA, neurosteroids and depressant compounds that act on the GABAA receptor, 
and that this increase is reduced in the presence of GABAA receptor antagonists [15,40,43,44]. 
We wanted to test whether this indirect assay of the GABAA receptor activity, based on the 
allosteric increase by GABA of the binding of benzodiazepines, could be used as an alternative 
testing assay for the GABAA receptor function. Figure 1 shows the concentration-response curves 
for bicuculline (Figure 1A) and picrotoxinin (Figure 1B) against [3H]-flunitrazepam binding and 
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36Cl- uptake in the presence of 100 µM GABA in primary cultures of cortical neurons. The two 
assays gave IC50 values that were not statistically significantly different (44 ± 6 µM and 36 ± 7 
µM for bicuculline, and 76 ± 21 µM and 37 ± 6 µM for picrotoxinin, against 36Cl- uptake and [3H]-
flunitrazepam assays, respectively; p > 0.1). Reference compounds that were found to inhibit the 
36Cl- influx assay were tested using the [3H]-flunitrazepam binding assay. Figures 2A and 2B 
show the concentration-response curves for some of the compounds listed in Table 1. Figure 3 
shows the correlation between IC50 values for [3H]-flunitrazepam binding and 36Cl-uptake in the 
presence of 100 µM GABA in primary cultures of cortical neurons. A high correlation (r2 = 0.9108; 
p < 0.0001) and a slope value of 1.03 was found. 
We also tested whether reference compounds could inhibit [3H]-GABA uptake, since a 
defect in the GABA transport system would result in an excess of extracellular GABA and lead to 
increased activity of neuronal GABA receptors, which would produce depression. Ten out of the 
twenty-three chemicals tested from the 1st set of reference compounds inhibited [3H]-GABA 
uptake in primary cultured cortical neurons. Table 2 shows the IC20, IC50 and IC80 values for these 
compounds.  
 
3.2. In vitro assays of glutamate neurotransmission and of cell membrane depolarization 
We have previously reported that primary cultures of cerebellar granule cells express 
NMDA- and AMPA/kainate-glutamate receptors and the neuronal transporter EAAT3 [2,3,12,41]. 
Activation of ionotropic glutamate receptors results in a Ca2+ influx through the NMDA receptor 
when the membrane is depolarized or in a Na+ influx through AMPA and kainate receptors 
leading to cell membrane depolarization.  
We tested the 1st set of reference chemicals against [3H]-aspartate uptake and against 
the increase of intracellular calcium ([Ca2+]i) in Mg2+-free buffer (Mg2+ blocks NMDA receptor). 
Five out of the twenty-three chemicals tested from the 1st set of reference compounds inhibited 
 16
[3H]-aspartate uptake in cultured cerebellar granule cells. Table 2 shows the IC20, IC50 and IC80 
values for these compounds. Complete inhibition of glutamate transport by digoxin, mercuric 
chloride, pentachlorophenol and SDS resulted in a net accumulation of extracellular glutamate 
that was even higher than that produced by exposing the cells to a high depolarizing stimulus of 
100 mM KCl (data not shown). This extracellular glutamate accumulation was not induced by 
malathion, which did not completely inhibit [3H]-aspartate uptake. When assessing [Ca2+]i, three 
out of the twenty-three chemicals tested from the 1st set of reference compounds increased 
intracellular calcium as determined by Fluo-3 fluorescence (digoxin, EC50: 29 µM; mercuric 
chloride, EC50: 9 µM, and pentachlorophenol, EC50: 38 µM).  
We tested the effect of the 1st set of reference compounds against cell membrane 
potential in primary cultures of cortical neurons. Nine out of the twenty-three chemicals tested 
modified basal FMP fluorescence. Figure 4 shows the concentration-response curves for the 
compounds that modified basal cell membrane potential. We also tested whether this assay could 
be used to identify compounds that inactivate neuronal Na+ channels, as this mechanism 
underlies the effects of some animal toxins, anaesthetics and anticonvulsant drugs. Veratridine 
specifically causes persistent activation of Na+ channels and increases FMP fluorescence in 
cultured neurons [41]. The increase in fluorescence induced by 20 µM veratridine was inhibited 
by carbamazepine (IC50 = 120 ± 16 µM, n = 3) in agreement with its mechanism of action 
inactivating Na+ channels [26]. Carbamazepine did not modify FMP fluorescence, indicating that it 
does not modify cell membrane potential by itself.  
 
3.3. Cell viability 
The first set of reference compounds were analyzed for their effects on cell viability after 
30 min exposure. This exposure time was slightly longer than that used in the neurofunctional 
assays (5 – 20 minutes). Only sodium lauryl sulphate (SDS) released intracellular LDH (IC50 = 
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2.2E-4 ± 0.3E-4 M) indicating cell membrane leakage. SDS also reduced mitochondrial activity at 
similar concentrations. Lower concentrations of SDS (≤ 1E-4 M) did not release LDH or reduce 
mitochondrial activity. Pentachlorophenol reduced mitochondrial activity (IC50 = 6.9E-5 ± 0.7E-5 
M) without releasing intracellular LDH, suggesting that mitochondria failure preceded cell 
membrane damage. Mercuric chloride also reduced mitochondrial activity (IC50 = 4.7E-6 ± 0.3E-6 
M), however, the effect of mercuric chloride on cell membrane integrity could not be determined 
due to the interference of Hg2+ with the LDH assay. The 2nd set of reference compounds did not 
produce cell cytotoxicity at the concentrations used in the functional GABAA receptor, as 
visualized by phase-contrast optical microscopy (data not shown). 
 
3.4. Predictive value of the in vitro neurofunctional assays 
Figure 5 shows a mosaic colour diagram that summarizes human toxicity data [37] and in 
vitro neural data for the compounds analyzed. Basal cytotoxicity data on the non-neural cell line 
3T3 [37] is also included, to compare in vitro neuronal endpoints and basal cytotoxicity. This 
comparison allowed us to establish neurotoxic alerts for the compounds that were more active at 
the neuronal than at the basal cytotoxicity endpoints in the 3T3 cell line. The GABAA receptor and 
the cell membrane potential assays were the tests that identified most compounds. For the most 
toxic compounds analyzed (human blood lethal concentration –LC50- values < 1E-5 M; black and 
blue colours in the diagram), the GABAA receptor and the FMP assays produced a neurotoxic 
alert with respect to the cytotoxicity 3T3 assay for methadone, lindane, malathion, parathion, 
strychnine and digoxin. Atropine and nicotine were recognized by the neurotoxic assays at 
concentrations similar to those producing cytotoxicity in the 3T3 cell line, whereas colchicine and 
verapamil did not produce a neurotoxic alert. For the compounds causing medium levels of 
toxicity (human blood LC50 values in the range 1E-5 M to 1E-3 M; pink and yellow colours), the 
neuronal GABAA receptor and the FMP assays gave a neurotoxic alert for diazepam, rifampicine, 
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caffeine, phenobarbital and pentachlorophenol, while warfarin, carbamazepine and mercuric 
chloride were recognized by the neural assays at concentrations similar to those producing 
cytotoxicity in the 3T3 cell line. Mercuric chloride produced a neurotoxic alert in the GABA uptake 
and glutamate uptake assays. Compounds whose toxic blood concentrations were < 1E-3 M 
(green and white colours) did not modify any of the neural endpoints studied. Isopropyl alcohol 
was an exception, since it was detected in the GABAA receptor assay as a neuroactive 
compound.  
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4.- Discussion 
In this work we provide evidence that in vitro cell-based functional neuronal tests can be used to 
identify chemical compounds that interfere with excitatory and inhibitory neurotransmission. 
Fifteen out of the twenty-one compounds in the first set of chemicals tested were identified as 
toxic by at least one of the five neuronal endpoints assayed in primary cultured neurons. 
Acetaminophen, acetylsalicylic acid, sodium valproate, glufosinate ammonium, ethanol and 
cycloheximide did not modify the assayed endpoints up to 1 mM. However, these compounds are 
known to be of low acute toxicity in humans and rats. The GABAA receptor assay identified the 
highest number of agents tested from the 1st set of reference compounds, among them atropine, 
lindane, malathion, pentachlorophenol, carbamazepine, and methadone, which result in seizures 
after severe human intoxication (Clemedson and Kolman, private communication within the 
AcuteTox consortium, forthcoming). Furthermore, diazepam, phenobarbital, chloral hydrate and 
isopropyl alcohol were recognized as GABAA receptor potentiators; they are CNS depressants at 
therapeutic and toxic doses. Because of the high capacity of the GABAA receptor to recognize 
neurotoxic compounds (even when the receptor was not their primary neuronal target) we 
extended this assay to the second set of 36 reference compounds. The pesticide parathion, 
which shares with malathion a phosphothiol group, was also identified as toxic by the GABAA 
receptor. Strychnine, a competitive antagonist of the glycine receptor-operated Cl- channel, also 
inhibited the GABAA receptor-operated Cl- channel; however, it was less potent on the GABAA 
than the glycine receptor [45]. The oral contraceptive hormone 17α-ethynylestradiol was also 
identified as toxic by the GABAA receptor assay. It has been reported that ß-estradiol and its 
derivative 17α-ethynylestradiol reduce the effect of GABA on human recombinant rho-1-subunit 
GABA receptors [24], in agreement with a recent report suggesting that the proconvulsant-like 
effects of testosterone could be mediated by increased synthesis of 17 β-estradiol [33]. According 
to our results, 17α-ethynylestradiol might produce a toxic response in the form of seizures, 
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however at blood concentrations much higher than those required for its therapeutic use (95–160 
ng/L) (Clemedson and Kolman, private communication within the AcuteTox consortium, 
forthcoming). A literature search confirms the GABAA receptor effects for 61% of the compounds 
shown to be active in the present work, while there were no data for 36% of the compounds and 
one compound (epinephrine) was reported not to act on the GABAA receptor, although at 
concentrations far lower than those used in the present work (see Table 1 for the effects of 
compounds on the GABAA receptor and Table 1 in Supplementary Material for related 
references). With respect to the 27 compounds tested that did not show activity on the GABAA 
receptor in our assay, there are reports for 4 of them confirming our results and no data for 20 
compounds. Three compounds (valproate, caffeine and ethanol) have been demonstrated to be 
active, however, at higher concentrations than those used in this study. Only one compound, 
amitryptyline has been reported to inhibit GABAA receptor function but was not recognized in our 
assay.  
The GABAA receptor has binding and recognition sites for a multiplicity of drugs and 
chemicals, including benzodiazepines, barbiturates, neurosteroids, anaesthetics, avermectin, 
polychlorocycloalkane pesticides, Zn2+ and lanthanides [25,36,49]. It is structurally composed of 5 
subunits (two α, two β and one γ), the interface between the α and β subunits and between the 
α and γ subunits allocate the binding sites for GABA and benzodiazepines, respectively. Each 
subunit has extracellular C- and N-terminus domains and four transmembrane domains (TM1–4). 
While TM2 faces the lumen of the Cl- channel and TM4 is anchored in the lipid membrane, the 
transmembrane segments TM1 and TM3 interact with the neighbouring subunit. It has been 
proposed that such an arrangement would allow conformational flexibility and would provide the 
receptor with space or cavities for putative binding sites. This model allows for new drug binding 
sites to be proposed [20]. Therefore, the GABAA receptor has a high capacity to be targeted by a 
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wide range of chemicals. In fact, it has been reported that several nicotinic antagonists also 
inhibited GABAA receptor function [35].  
In this work, the GABAA receptor activity was determined by measuring the uptake of 
36Cl- induced by GABA in primary neuronal cultures. As we previously reported, this assay 
recognizes both chemicals that potentiate and those that inhibit the GABAA receptor [15,32, 
44,45]. However, the high energy of the radionuclide 36Cl (710 keV) requires the use of 
acrylamide screens and tube-holders to protect the analyst against the high beta-radiation 
emitted by 36Cl. Furthermore, 36Cl has a long disintegration half-life (3 x 105 years). All of this 
poses technical and environmental drawbacks for the acceptance of this test in high-throughput 
screening frameworks. Therefore, developing an assay for the GABAA receptor using 3H (19 keV; 
12-year half-life) instead of 36Cl will result in a clear improvement. It has been demonstrated that 
binding to a site at the GABAA receptor exerts allosteric modulation on the other independent 
recognition sites [11,15, 43, 44]. In this work we provide evidence that the binding of [3H]-
flunitrazepam in the presence of GABA can be used as a functional assay for the GABAA 
receptor. The good correlation between IC50 values for GABA-induced Cl- influx and GABA-
induced increase of flunitrazepam binding for compounds that inhibited the GABAA receptor 
suggests that both assays can be used indistinctly to test for inhibition or blocking of GABAA 
receptor activity. This binding assay, although still using tritium radioactivity, is much more 
friendly than the radiometric 36Cl- influx assay and much more prone to be automated. 
Standardization of this method and further validation could give rise to a high-throughput assay 
for the activity of chemicals on the GABAA receptor. Electrophysiology is the technique that 
provides most information on GABAA receptor function; however, this methodology requires very 
specific equipment, high researcher expertise and is not amenable to high throughput. The 
development of multielectrode chambers where primary neuronal cultures can be grown is also 
creating expectations for their use in functional neurotoxicity screening [4,46].  
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Chemical compounds may produce hyperexcitability by directly activating ionotropic 
glutamate receptors or by increasing extracellular glutamate, which in turn will activate these 
receptors, resulting in degeneration of neurons through a process known as excitotoxicity [23,31]. 
Inactivation of glutamate released from neural cells is accomplished by efficient uptake through 
glutamate transporters expressed in glial cells and neurons. Few compounds from the 1st set of 
reference compounds were demonstrated to be active on the NMDA-glutamate receptor. Since 
these compounds also completely inhibited [3H]-aspartate uptake and increased the extracellular 
concentration of glutamate, the NMDA receptor could be activated as an indirect result of the 
accumulation of extracellular glutamate. The EC50 values for the increase in [Ca2+] were similar to 
the IC50 values for glutamate transport. Neither was glutamate transport a sensitive endpoint, 
since it recognized very few compounds. In contrast, GABA transport was inhibited by 10 
chemicals from the 1st set of reference compounds, including some commonly abused drugs, 
such as methadone and amphetamine. These are more potent inhibitors of monoamine transport 
(IC50 values: 0.3–90 µM; [5,13,17,34]) than of GABA transport (170–1400 µM; this work). 
However, since GABA and monoaminergic transporters, but not glutamate transporters, belong to 
the same slc6 protein family [6], the inhibition of the GABA transport in cultured cortical neurons 
could be used as a specific alert for neurotoxicity. Furthermore, compounds like tiagabine that 
inhibit GABA uptake might have anticonvulsant properties [16].  
In this work we used the cell membrane potential fluorescent probe FMP as a non-
specific assay to identify compounds that modify neuronal excitability, whatever the mechanism. 
We recently reported that the FMP fluorescence assay for cell membrane potential responds to 
different depolarizing stimuli mediated by voltage- and receptor-operated ion channels in cultured 
neurons. KCl, veratridine, and glutamate and kainate increase FMP fluorescence at 
concentrations compatible with activation of Na+ and AMPA/kainate receptors, respectively [41]. 
Nine out of the twenty-three chemicals in the 1st set of reference compounds modified FMP 
 23
fluorescence. The assay was able to recognize compounds acting at different neuronal 
endpoints, such as nicotine at the nACh receptor and digoxin which inhibits Na+/K+/ATPase. The 
increase in FMP fluorescence by the microtubule disruptor agent colchicine is in agreement with 
the effects observed in cardiac myocytes, where colchicine increases sodium but not calcium 
currents [29]. The decrease of FMP fluorescence caused by caffeine could be indicative of a 
hyperpolarizing shift of membrane potential after ryanodine receptor activation, as demonstrated 
in mammalian neurons [18]. Neither lindane nor malathion, which inhibited GABAA receptor 
activity, modified membrane potential. The effect of SDS on FMP fluorescence could be attributed 
to membrane disruption since EC50 values for FMP fluorescence and cytotoxicity in cortical 
neurons were similar (1 – 3 E-4 M). Furthermore, the compounds that showed sensitivity to 
glutamate endpoints (mercuric chloride, pentachlorophenol and digoxin) were also recognized by 
the cell membrane potential assay. The advantages of this method are that it can recognize 
compounds interfering with different neuronal targets that modify neuronal excitability and that the 
assay can be easily brought to high-throughput standards. 
A crucial point when validating alternative methods is the comparison/correlation with 
tests in current use. Although the majority of traditional animal test methods have not been 
validated, they are routinely used as reference test methods for validation. As stated in the 
workshop on “Points of Reference in the Validation Process” of alternative test methods held at 
the ECVAM (European Centre for Validation of Alternative Methods) in 2006 [21], the ideal 
situation when validating alternative methods addressing human health (as in toxicology testing) 
would be to compare in vitro data with human data. This would allow an optimal relevance of 
assessment. Lethal human blood concentrations, LC50, for the tested chemicals have recently 
been calculated [37] from reported human toxicity data. Comparison of the in vitro neural results 
obtained in this work with basal cytotoxicity in the human cell line 3T3 and with human in vivo 
data [37] shows that neurotoxic alerts have been established for compounds known to be 
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neuroactive, causing hyperexcitability or depression of the nervous system (lindane, malathion, 
parathion, strychnine, methadone, digoxin, diazepam, phenobarbital and caffeine). Except for 
phenobarbital and caffeine, these compounds were outliers when their toxicity was predicted from 
in vitro basal cytotoxicity assays [37]. We can conclude that a better prediction of acute human 
toxicity has been obtained by using in vitro neuronal functional assays. Nicotine, also an outlier in 
the basal cytotoxicity assay prediction, was recognized by the neuronal FMP assay, however, its 
toxicity was not better predicted. The FMP assay should be refined to detect compounds acting 
on the nicotinic acetylcholine receptor. In this work, the GABAA receptor, the GABA uptake and 
the cell membrane potential assays were those that recognized the highest number of chemicals 
at low concentrations. Furthermore, we have previously reported that the organophosphate 
pesticides dichlorvos and malathion inhibited AChE activity in primary cultures of cortical neurons 
[4], a mechanism that results in central and peripheral nervous system excitability.  
In this work we used primary cultures of cortical and of cerebellar granule neurons 
because they are widely used and they are produced in high yields. They are also well 
characterized in terms of pre-synaptic and post-synaptic amino acid and acetylcholine 
neurotransmission; the major neurotransmitter systems involved in acute neurotoxicity. However, 
it can be argued that these cultures may not recognize chemicals that exhibit regional and cellular 
specificity such as, for example, dopaminergic toxins. The use of primary cultures obtained from 
the whole cerebral tissue could overcome this problem once they are fully characterized. 
Neurogenesis occurs at different embryonic ages for the different cell types in the brain, thus 
determining the viability and differentiation of the cells in culture.   
We conclude that in vitro evaluation of neural endpoints in primary neuronal cultures may 
identify compounds that produce acute neurotoxicity in humans, provided that in vitro models 
expressing neuronal targets relevant for acute neural dysfunctions are used. We provide 
evidence that test methods based on the measurement of the activity of GABAA receptors, GABA 
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transport, AChE and on the measurement of the cell membrane potential are potent candidates to 
be included in an in vitro testing strategy for neurotoxicity. Further studies and validation of these 
methods are needed to progress in the development and implementation of medium- to high-
throughput alternative methods for the assessment of human neurotoxicity. 
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Table 1.- Concentrations of reference chemicals that were effective on the GABAA receptor in 
primary cultured cortical neurons.  
 
compound IC20 (M) IC50 (M) IC80 (M) Imax (%) 
 
Inhibition > 80% at the maximal concentration tested 
17α-Ethynylestradiol 6.3E-7 ± 3.0E-7 2.5E-6 ± 1.2E-6 1.1E-5 ± 0.4E-5 89 ± 11 
Atropine 3.5E-5 ± 2.3E-5 2.1E-4 ± 1.4E-4 1.3E-3 ± 0.8E-3 85 ± 10 
2,4-
Dichlorophenoxyacetic 
acid 
6.0E-4 ± 4.0E-4 1.8E-3 ± 1.2E-3 5.8E-3 ± 3.9E-3 100 ± 0 
Lindane 2.6E-5 ± 0.1E-5 3.1E-5 ± 0.2E-5 3.7E-5 ± 0.2E-5 100 ± 0 
Malathion 2.5E-6 ± 0.7E-6 3.9E-6 ± 1.9E-6 1.1E-4 ± 0.3E-4 100 ± 0 
Parathion 1.3E-6 ± 0.4E-6 5.3E-6 ± 1.6E-6 2.1E-5 ± 0.6E-5 94 ± 6 
Pentachlorophenol 2.2E-6 ± 0.8E-6 3.9E-6 ± 1.5E-6 7.8E-6 ± 2.6E-6 99 ± 1 
Rifampicine 1.2E-6 ±0.3E-6 8.9E-6 ± 2.7E-6 7.0E-5 ± 2.1E-5 84 ± 8 
Sodium lauryl sulphate 1.4E-6 ± 0.5E-6 2.6E-6 ± 0.9E-6 5.2E-6 ± 1.8E-6 98 ± 2 
Strychnine 9.5E-6 ± 7.3E-6 3.8E-5 ± 2.9E-5 1.5E-4 ± 1.2E-4 100 ± 0 
Verapamil 2.4E-5 ± 0.9E-5 1.7E-4 ± 0.6E-4 1.2E-3 ± 0.4E-3 81 ± 6 
Warfarin 2.0E-4 ± 1.5E-4 8.0E-4 ± 6.0E-4 3.1E-3 ± 2.3E-3 91 ± 10 
 
50% < Inhibition at the highest concentration tested < 80% 
Acrylaldehyde 2.7E-3 ± 0.3E-3 1.1E-2 ± 0.1E-2  75 ± 5 
t-Butylhydroperoxide 9.5E-3 ± 4.8E-3 3.8E-2 ± 1.9E-2  68 ± 11 
Carbamazepine 1.1E-5 ± 0.2E-5 2.3E-4 ± 0.4E-4  52 ± 12 
Colchicine 1.5E-4 ± 0.3E-4 4.8E-4 ± 0.8E-4  72 ± 5 
Cyclosporine A 7.7E-6 ± 3.7E-6 3.1E-5 ± 1.5E-5  64 ± 13 
(-)-Epinephrine bitartrate 2.6E-3 ± 1.4E-3 1.2E-3 ± 0.5E-3  67 ± 17 
5-Fluorouracil 7.1E-5 ± 3.5E-5 2.8E-4 ± 1.4E-4  61 ± 3 
Lithium sulphate 2.1E-2 ± 0.6E-2 8.5E-2 ± 2.6E-2  55 ± 3 
Methadone 3.1E-4 ± 1.1E-4 7.4E-4 ± 2.7E-4  69 ± 16 
 
20% < Inhibition at the highest concentration tested < 50% 
Cadmium chloride 3.0E-4 ± 0.8E-4   41 ± 6 
Digoxin 1.0E-4 ± 0.3E-4   39 ± 2 
  
EC50 Potentiation (M) 
 
Emax (%) 
Diazepam 2.5E-8 ± 1.1E-8 54 ± 13 
Phenobarbital 7.2E-5 ± 3.7E-5 133 ± 42 
Isopropyl alcohol 2.6 E-5 52 ± 8 
Mercuric chloride 1.4E-4 ± 1.3E-4 218 ± 27 
Chloral hydrate 8.7E-6 ± 0.9E-6 89 ± 12 
 
 
GABAA receptor activity was determined as percentage of 36Cl- uptake induced by 100 µM GABA 
(inhibition experiments) or 5 µM GABA (potentiation experiments). Values are mean ± S.E.M. (n 
= 3-4). Imax refers to the percentage of inhibition. Emax refers to the percentage of potentiation with 
respect to that induced by 100 µM GABA.  
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Table 2.- Concentrations of the 1st set of reference compounds that inhibited amino acid transport in cultured neurons.  
 
 GABA transport glutamate transport 
compound IC20 (M) IC50 (M) IC80 (M) IC20 (M) IC50 (M) IC80 (M) 
Mercuric chloride 4.1E-6 ± 1.0E-6 6.8E-6 ± 1.6E-6 1.1E-5 ± 0.3E-5 1.2E-6 ± 0.5E-6 1.6E-6 ± 0.6E-6 2.2E-6 ± 0.9E-6 
Pentachlorophenol 1.4E-4 ± 0.5E-4 2.0E-4 ± 0.5E-4 3.0E-4 ±0.5E-4 4.8E-6 ± 2.2E-6 1.6E-5 ± 0.7E-5 5.1E-5 ± 2.4E-5 
Sodium lauryl sulphate 8.8E-5 ±0.3E-5 9.9E-5 ± 0.4E-5 1.1E-4 ± 0.04E-4 4.3E-5 ± 0.5E-5 7.0E-5 ± 0.9E-5 1.2E-4 ± 0.1E-4 
Methadone 5.9E-5 ±0.6E-5 1.7E-4 ± 0.2E-4 4.7E-4 ± 0.5E-4 > 1E-3   
Verapamil 4.7E-5 ± 0.6E-5 1.4E-4 ± 0.2E-4 3.9E-4 ± 0.5E-4 >1E-3   
digoxin 2.1E-5 ± 0.2E-5 1.4E-4 ± 0.1E-4 > 5E-4 3.1E-6 ± 1.8E-6 1.2E-5 ± 0.7E-5 4.7E-5 ± 2.9E-5 
diazepam 3.9E-5 ± 0.3E-5 1.3E-4 ± 0.1E-4  > 1E-3   
amphetamine 8.2E-5 ± 3.0E-5 1.4E-3 ± 0.5E-3  > 1E-3   
malathion >1E-3   9.2E-4 ± 0.1E-4 > 1E-3  
Isopropyl alcohol 8.9E-3 ± 4.1E-3   > 1E-3   
carbamazepine 8.1E-4 ± 3.5E-4   > 1E-3   
 
GABA and glutamate transport were determined as [3H]GABA uptake in cultured cortical neurons and [3H]-aspartate uptake in cultured cerebellar granule cells, 
respectively. Values are mean ± S.E.M. (n = 3).  
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Legends 
Figure 1.- GABAA receptor antagonists bicuculline (A) and picrotoxinin (B) inhibit the 36Cl- influx 
and the increase of [3H]-flunitrazepam binding induced by 100 µM GABA in primary cultures of 
cortical neurons. ■, 36Cl- influx assay; ▼, [3H]-flunitrazepam binding assay. Values are mean ± 
S.E.M of 3 independent experiments, each concentration point determined in triplicate. 
 
Figure 2.- Effect of compounds that inhibit GABA-induced 36Cl- influx on the allosteric response of 
[3H]-flunitrazepam binding induced by GABA in primary cultures of cortical neurons. A) 
pharmaceutical chemicals: ?, 17-α-ethynylestradiol; ■, methadone; ?, epinephrine bitartrate; 
?, atropine; ?, rifampicine; ?, colchicine; ?, verapamil; ?, carbamazepine. B) industrial and 
pesticide chemicals: ▲, sodium lauryl sulfate; ?, warfarin; ■, acrylaldehyde; ?, 2,4-
dichlorophenoxyacetic acid; ?, pentachlorophenol; ?, parathion; ?, malathion; ?, strychnine. 
Values are mean ± S.E.M (n = 3). Error bars are omitted for clarity. 
 
Figure 3.- Correlation between IC50 values for [3H]-flunitrazepam binding and 36-Cl-uptake in the 
presence of 100 µM GABA in primary cultures of cortical neurons for compounds that inhibited 
GABAA receptor activity. Sodium lauryl sulphate (SDS) value was excluded from the correlation.  
 
Figure 4.- Concentration-response curves for the effect of selected chemicals on cell membrane 
potential in primary cultures of cortical neurons. A) ?, colchicine; ?, methadone; ?, digoxin; 
?, mercury II chloride; ▲,nicotine. B) ?, caffeine; ?, verapamil; ?, pentachlorophenol; ■, 
sodium lauryl sulphate. Values are mean ± S.E.M of 3 independent experiments, each 
concentration point was determined in triplicate.  
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Figure 5.- Summary of in vivo / in vitro toxicity datafor the reference compounds. In vivo data 
represent human blood lethal concentrations (LC50), whereas in vitro data represent effective 
concentration values for the different neural cell assays performed in primary neuronal cultures 
and for the cytotoxicity assay performed in the 3T3 cell line. Colours indicate the range of 
concentrations (M) for the selected parameters: black, <1E-6; blue, 1E-6 – 1E-5; pink, 1E-5 – 1E-
4; yellow, 1E-4 – 1E-3; green: 1E-3 – 1E-2; white, 1E-2 – 5E-1 (human) or up to the highest 
concentration tested (in vitro; see Table 1, SI). Nd: not data; nt: not tested.  
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